CRSP

#1075
CRISPR Therapeutics AG
60.14
+1.66%
Sector:
Básica:
Profit Currency:
Rango diario
60.14
60.14
Rango anual
30.04
78.48
Cambio diario
+1.66%
Monthly Change
+10.76%
6 month change
+12.62%
Cambio anual
+41.17%
Cierres anteriores
59.16
Open
60.14
Bid
Ask
Low
60.14
High
60.14
Volumen
141
Open full chart

Financials

Overview Statement Statistics Dividends
Quarterly Annual
  • Market Capitalization 5.41 B
  • Employee 393
  • Founded 2013
  • CEO Samarth Kulkarni
  • Website www.crisprtx.com
  • Headquarter Switzerland
  • FIGI UNKNOWN
  • Industry Technology
Total revenue
Net income
Basic earnings per share (Basic EPS)
Total debt
Free cash flow
Cash & equivalents
Price to earnings ratio
-8.11
Price to sales ratio
1 343.5
Dividends per share
—
Dividend yield %
—

CRISPR Therapeutics AG

CRISPR Therapeutics AG is a Swiss–American biotechnology company headquartered in Zug, Switzerland. The company does business as CRISPR Therapeutics, Inc. in the United States. It was one of the first companies formed to utilize the CRISPR gene editing platform to develop medicines for the treatment of various rare and common diseases. The company has approximately 500 employees and has offices in Zug, Switzerland, Boston, Massachusetts, San Francisco, California and London, United Kingdom. Its manufacturing facility in Framingham, Massachusetts won the Facilities of the Year Award award in 2022. The company’s lead program, exagamglogene autotemcel, or exa-cel, was granted regulatory approval by the US Food and Drug Administration in December 2023.

Noticias